MIA researchers feature on prestigious Highly Cited Researchers 2020 List
18 November 2020
Melanoma Institute Australia is proud to announce that MIA’s Co-Medical Directors, Professor Georgina Long AO and Professor Richard Scolyer, as well as MIA Faculty member Associate Professor Alex Menzies and former Faculty member Professor Rick Kefford AM, have been named on the annual Highly Cited Researchers™ 2020 list from Clarivate.
The highly anticipated annual list is the “who’s who” of the scientific elite from across the globe. It identifies researchers who demonstrated significant influence in their chosen field or fields through the publication of multiple highly cited papers during the last decade.
Their names are drawn from the publications that rank in the top 1% by citations for field and publication year in the Web of Science™ citation index.
According to Clarivate, 6,167 researchers from more than 60 countries and regions have been recognized this year, with Australian research institutes continuing to punch above their weight. In a country of just 25 million, the number of Australian researchers recognized in 2020 is 305.
MIA Co-Medical Director Professor Georgina Long AO, whose video interview with Clarivate is featured online, said:
“This accolade is recognition of the ground-breaking work being carried out by the entire team at Melanoma Institute Australia as we continue our quest to develop treatments that will ultimately save the lives of all melanoma patients.”
Fellow Co-Medical Director of MIA Professor Richard Scolyer said:
“It is an honour to again be included on this list alongside several other MIA researchers and clinicians. It shows the phenomenal and ongoing impact that MIA’s work and research is having around the world.”
David Pendlebury, Senior Citation Analyst at the Institute for Scientific Information at Clarivate said:
“In the race for knowledge, it is human capital that is fundamental and this list identifies and celebrates exceptional individual researchers from Melanoma Institute Australia who are having a great impact on the research community as measured by the rate at which their work is being cited by others.”
Melanoma Institute Australia is affiliated with The University of Sydney
The best ever results seen in metastatic melanoma treatment have been presented at the International ASCO Conference.
We sat down for a short Q&A with our Clinical Research Fellow Sangeetha Ramanujam.
Today marks International Clinical Trials Day held on May 20 each year celebrating how far clinicians have come in the field of research.
We sat down with MIA Practice Manager, Sherrie D'Souza and got an insight into the day of life of her role.
Dr Long was nomitated for the InStyle Women In Style Awards in the Science and Environment category.
The Federal Government’s 2015-16 Budget was announced this week with a boost for medical research funding.
The Association's members include prominent surgeons from around the world.
MIA leads the world-first study that finds anti–PD-1 antibody pembrolizumab increases the survival of patients
This is a landmark study, the first in a class of drugs that will change the future of treatment for all cancers.
Australia is the first country in the world to register anti-PD1 for the first line treatment of unresectable or metastatic melanoma in adults.
We have a winner!
Professor John Thompson, Executive Director at Melanoma Institute Australia, was one of 116 fellows appointed to the new Australian Academy of Health and Medical Sciences at a ceremony in Canberra on the 25th March.
Federal Minister for Health, the Hon. Sussan Ley, announced more than $14 million in funding for a research program to study the molecular determinants of risk, progression and treatment response in melanoma.
If you would like to download a bib for your Melanoma March, we have a selection for you to choose from, print and bring along with you on the day.
Manly Melanoma March has changed to a new location.
We did a short Q&A with two sisters who are raising funds for Melanoma March after sadly losing their mother in 2009. This is their second march and they have shared with us their fundraising tips.
We want to share with you what your valuable Melanoma March donation and fundraising goes towards and our Research Director, Graham Mann explains the national research project the funds will be going towards.
Evaluation of Groin Lymphadenectomy Extent for Metastatic Melanoma (EAGLE FM) clinical trial has recruited its first patient.
You are invited to provide comments for consideration by the Pharmaceutical Benefits Advisory Committee (PBAC). The PBAC will consider the registration of the anti-PD1 drug, Keytruda (pembrolizumab) at the next meeting in March.
Melanoma patient Joel Allsop was congratulated today on completing his participation in the international surgical clinical trial, known as MSLT-II. He was the first person in the world to complete the 10 years of follow-up for this trial.